정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2221 | Completed | An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Biological: Mesenchymal stem cell | Phase 1 | Rohto Pharmaceutical Co., Ltd. | INDUSTRY | 6 | All | 20 Years | Osaka University Hospital, Suita, Osaka, Japan |
| 2220 | Active, not recruiting | An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY | Moderate and Severe COVID-19 | Other: Standard of Care (SoC) Drug: Remdesivir |
Phase 3 | Professor Dr. Bernd Muhlbauer, Dept. of Statistics and Medical Biometry, University of Bremen, INSERM (Institut national de la sante et de la recherche medicale), Paris, France, World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland | OTHER | 400 | All | 18 Years | Gesundheit Nord gGmbH, Bremen, Germany Universitatsklinikum Gießen, Gießen, Germany Medizinische Hochschule Hannover (MHH), Hannover, Germany Technische Universitat Munchen (TUM), Munchen, Germany |
| 2219 | Completed | An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial | COVID-19 | Drug: Hydroxychloroquine Drug: Lopinavir / Ritonavir Drug: Interferon Beta-1A Drug: Interferon Beta-1B |
Phase 2 | Shahid Beheshti University of Medical Sciences | OTHER | 60 | All | 18 Years | Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of |
| 2218 | Recruiting | An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 | Inflammatory Response | Drug: Icosapent ethyl | Phase 2 | Canadian Medical and Surgical Knowledge Translation Research Group, Amarin Corporation, HLS Therapeutics, Inc | OTHER | 100 | All | 18 Years ~ 75 Years | North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada |
| 2217 | Active, not recruiting | An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19 | COVID-19 | Drug: Aprotinin | Not Applicable | Aviron LLC | INDUSTRY | 30 | All | 18 Years | Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation |
| 2216 | Completed | An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19 | Preventive Immunization COVID-19 | Biological: Gam-COVID-Vac Lyo | Phase 2 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, Acellena Contract Drug Research and Development | OTHER | 38 | All | 18 Years ~ 60 Years | Sechenov First Moscow State Medical University, Moscow, Russian Federation |
| 2215 | Completed | An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19 | Preventive Immunization COVID-19 | Biological: Gam-COVID-Vac | Phase 2 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, Acellena Contract Drug Research and Development | OTHER | 38 | All | 18 Years ~ 60 Years | Main military clinical hospital named after academician N. N. Burdenko, Moscow, Russian Federation |